Research graph
References from Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies. Local targets link to admitted publications; unresolved targets remain external evidence.
Novel therapeutic targets in dermatomyositis
10.1111/1346-8138.17170 · 2024 · External reference
Dermatomyositis: practical guidance and unmet needs
10.2147/itt.s381472 · 2024 · External reference
Idiopathic inflammatory myopathies: current insights and future frontiers
10.1016/s2665-9913(23)00322-3 · 2024 · External reference
10.1016/j.jaad.2010.10.016
10.1016/j.jaad.2010.10.016 · External reference
Pharmacological strategies in dermatomyositis: current treatments and future directions
10.12659/msm.944564 · 2024 · External reference
Immunotherapies for immune-mediated myopathies: a current perspective
10.1007/s13311-015-0394-2 · 2016 · External reference
10.1056/nejmoa2117912
10.1056/nejmoa2117912 · External reference
Combination therapy of prednisone, azathioprine, and hydroxychloroquine in patient with dermatomyositis
2024 · External reference
Inhibiting interferon pathways in dermatomyositis: rationale and preliminary evidence
10.1007/s40674-021-00182-1 · 2021 · External reference
10.55563/clinexprheumatol/hxin6o
10.55563/clinexprheumatol/hxin6o · External reference
10.1111/bpa.12955
10.1111/bpa.12955 · External reference
Safety, tolerability, and pharmacokinetics of PF-06823859, an anti-interferon beta monoclonal antibody: a randomized, phase I, single- and multiple-ascending-dose study
10.1002/cpdd.887 · 2021 · External reference
10.1016/s0140-6736(24)02071-3
10.1016/s0140-6736(24)02071-3 · External reference
10.1002/acr.20532
10.1002/acr.20532 · External reference
American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
10.1002/art.40064 · 2016 · External reference
American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
10.1136/annrheumdis-2017-211400 · 2016 · External reference
10.1111/bjd.13915
10.1111/bjd.13915 · External reference
Long-term safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: follow-up data from a 3-year open-label extension study
10.1016/j.xjidi.2024.100311 · 2025 · External reference
Optimization of the diagnostic capacity of traditional biomarkers in muscle damage and its use in the diagnosis of dermatomyositis and polymyositis
2024 · External reference
Dazukibart for dermatomyositis: expanding the therapeutic arsenal
10.21037/atm-25-44 · 2025 · External reference
Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum
10.1016/j.ard.2026.02.018 · 2026 · External reference
